The Irish Prostate Cancer Outcomes Research (IPCOR) study published its annual report for 2018 in November. For the first time, the report outlines demographic and diagnostic clinical data on over 4800 men who were newly diagnosed with prostate cancer in 15 participating hospitals across Ireland from February 2016 to December 2017.
IPCOR has been funded since 2014 by the Movember Foundation, in partnership with the Irish Cancer Society, with the aim of establishing a national prostate cancer registry which collects detailed clinical and patient-reported data on men’s prostate cancer journeys from the time of diagnosis, throughout treatment and beyond. IPCOR data provides the information necessary to inform and improve the care of men living with the disease and the consequences of its treatments.
The IPCOR report describes a man’s typical diagnostic journey and investigates aspects of this journey in more detail. The figure above shows the timeline of a man’s diagnostic journey. At the start of the journey, a man attends his GP who carries out a PSA (Prostate Specific Antigen) blood test. The results of the PSA test show an elevated PSA level leading the referral of the man to a urology clinic for further tests for prostate cancer. The man then has a prostate biopsy and a diagnosis of prostate cancer is confirmed by a pathologist. The man is informed of his diagnosis by his clinician. The interrogation of this timeline is important as it represents the initial experience of thousands of men diagnosed with prostate cancer every year in Ireland. This journey needs to be supported to benefit the man, his partner and his family.
To find out more about a man’s diagnostic journey and the results from the IPCOR study, you can view the report at www.ipcor.ie/Research-and-Publications and at https://www.crdi.ie/irish-prostate-cancer-outcomes-research-ipcor/.